Biodesix (NASDAQ:BDSX) Posts Earnings Results, Hits Estimates

Biodesix (NASDAQ:BDSX) posted its quarterly earnings results on Thursday. The company reported ($0.75) EPS for the quarter, hitting analysts’ consensus estimates of ($0.75), FiscalAI reports. The firm had revenue of $24.04 million during the quarter, compared to analyst estimates of $27.49 million. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%.

Here are the key takeaways from Biodesix’s conference call:

• Biodesix reported Q3 revenue of $24.0 million, up 10%, and diagnostic test volume up 24%, but results fell short of expectations. Management attributed the shortfall to fewer sales representatives than planned, weaker-than-expected primary-care seasonality and delayed development-services projects.
• The company lowered its 2026 revenue outlook to $101 million–$103 million, or about 15% growth at the midpoint. Management expects development-services revenue to remain near $1 million in Q4, with many projects shifting into 2027; it also said a higher mix of Nodify CDT tests is weighing on average revenue per test.
• Commercial capacity has improved to about 110 representatives, with a target of 115 by year-end. Management said October was its strongest month of new-physician acquisition this year and expects added sales capacity and improved forecasting to support a recovery, while noting new hires take time to ramp.
• Biodesix cited the CHEST lung-nodule management framework and early enterprise-wide integrations at two major health systems as support for broader use of its Nodify tests. These system-level rollouts could make adoption more scalable, though management cautioned that implementation takes time.
• The company is expanding beyond blood-based diagnostics with a radiomic lung-nodule test targeted for commercialization in 2028 and two MRD assay programs developed with Bio-Rad and Thermo Fisher. These initiatives broaden its longer-term opportunity, but remain in development.

Biodesix Price Performance

BDSX traded down $1.65 on Thursday, reaching $19.84. The company had a trading volume of 185,258 shares, compared to its average volume of 78,704. The business has a 50 day simple moving average of $25.93 and a 200 day simple moving average of $18.90. The company has a market cap of $209.33 million, a price-to-earnings ratio of -6.26 and a beta of 0.65. The company has a debt-to-equity ratio of 5.12, a quick ratio of 2.85 and a current ratio of 2.85. Biodesix has a 52-week low of $5.26 and a 52-week high of $31.97.

Insider Transactions at Biodesix

In related news, Director Jack Schuler purchased 15,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was acquired at an average price of $24.47 per share, with a total value of $367,050.00. Following the purchase, the director directly owned 555,810 shares in the company, valued at approximately $13,600,670.70. This represents a 2.77% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have purchased 42,600 shares of company stock worth $1,033,062 in the last three months. Insiders own 23.20% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on BDSX shares. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. Canaccord Genuity Group increased their price objective on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. HC Wainwright reissued a “buy” rating on shares of Biodesix in a research note on Thursday, October 22nd. Finally, TD Cowen restated a “buy” rating and set a $40.00 target price (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $36.25.

Biodesix Company Profile

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.